These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 38565994)

  • 1. An evaluation of the cost of human papilloma virus (HPV) vaccine delivery in Zambia.
    Simuyemba MC; Chama-Chiliba CM; Chompolola A; Sinyangwe A; Bchir A; Asiimwe G; Chibwesha C; Masiye F
    BMC Infect Dis; 2024 Apr; 24(1):369. PubMed ID: 38565994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Evaluation of the Cost of Human Papilloma Virus (HPV) Vaccine Delivery In Zambia.
    Simuyemba MC; Chama-Chiliba CM; Chompola A; Sinyangwe A; Bchir A; Asiimwe G; Masiye F; Chibwesha C
    Res Sq; 2023 May; ():. PubMed ID: 37398262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A case study using the United Republic of Tanzania: costing nationwide HPV vaccine delivery using the WHO Cervical Cancer Prevention and Control Costing Tool.
    Hutubessy R; Levin A; Wang S; Morgan W; Ally M; John T; Broutet N
    BMC Med; 2012 Nov; 10():136. PubMed ID: 23146319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Costs of delivering human papillomavirus vaccination using a one- or two-dose strategy in Tanzania.
    Hsiao A; Struckmann V; Stephani V; Mmbando D; Changalucha J; Baisley K; Levin A; Morgan W; Hutubessy R; Watson-Jones D; Whitworth H; Quentin W
    Vaccine; 2023 Jan; 41(2):372-379. PubMed ID: 36460537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost of human papillomavirus vaccine delivery in a single-age cohort, routine-based vaccination program in Senegal.
    Brennan T; Hidle A; Doshi RH; An Q; Loharikar A; Casey R; Badiane O; Ndiaye A; Diallo A; Loko Roka J; Mejia N; Abimbola T
    Vaccine; 2022 Mar; 40 Suppl 1(Suppl 1):A77-A84. PubMed ID: 34955325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experiences of operational costs of HPV vaccine delivery strategies in Gavi-supported demonstration projects.
    Botwright S; Holroyd T; Nanda S; Bloem P; Griffiths UK; Sidibe A; Hutubessy RCW
    PLoS One; 2017; 12(10):e0182663. PubMed ID: 29016596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Costs of delivering human papillomavirus vaccination to schoolgirls in Mwanza Region, Tanzania.
    Quentin W; Terris-Prestholt F; Changalucha J; Soteli S; Edmunds WJ; Hutubessy R; Ross DA; Kapiga S; Hayes R; Watson-Jones D
    BMC Med; 2012 Nov; 10():137. PubMed ID: 23148516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost of human papillomavirus vaccine delivery at district and health facility levels in Zimbabwe: A school-based vaccination program targeting multiple cohorts.
    Hidle A; Brennan T; Garon J; An Q; Loharikar A; Marembo J; Manangazira P; Mejia N; Abimbola T
    Vaccine; 2022 Mar; 40 Suppl 1(Suppl 1):A67-A76. PubMed ID: 35181152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost and operational context for national human papillomavirus (HPV) vaccine delivery in six low- and middle-income countries.
    Mvundura M; Slavkovsky R; Debellut F; Naddumba T; Bayeh A; Ndiaye C; Anena J; Vodicka E; Diop A; Gamage D; Musanabaganwa C; Tatkan G; Driwale A; Zelalem M; Badiane O; Ginige S; Hamilton E; Sibomana H; Lakew Y; Uwinkindi F; Dhufera A; Ampeire I; Kumar S; Lamontagne DS
    Vaccine; 2023 Nov; 41(49):7435-7443. PubMed ID: 37949752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Costs associated with delivering HPV vaccination in the context of the first year demonstration programme in southern Mozambique.
    Alonso S; Cambaco O; Maússe Y; Matsinhe G; Macete E; Menéndez C; Sicuri E; Sevene E; Munguambe K
    BMC Public Health; 2019 Aug; 19(1):1031. PubMed ID: 31370810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implementation of a human papillomavirus vaccination demonstration project in Malawi: successes and challenges.
    Msyamboza KP; Mwagomba BM; Valle M; Chiumia H; Phiri T
    BMC Public Health; 2017 Jun; 17(1):599. PubMed ID: 28651574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study.
    Jit M; Brisson M; Portnoy A; Hutubessy R
    Lancet Glob Health; 2014 Jul; 2(7):e406-14. PubMed ID: 25103394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of human papillomavirus (HPV) vaccination in Burkina Faso: a modelling study.
    Kiendrébéogo JA; Sidibe ARO; Compaoré GB; Nacanabo R; Sory O; Ouédraogo I; Nawaz S; Schuind AE; Clark A
    BMC Health Serv Res; 2023 Dec; 23(1):1338. PubMed ID: 38041075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. National introduction of human papillomavirus (HPV) vaccine in Tanzania: Programmatic decision-making and implementation.
    Mphuru A; Li AJ; Kyesi F; Mwengee W; Mazige F; Nshunju R; Shayo B; Giattas MR; Loharikar A; Lyimo D
    Vaccine; 2022 Mar; 40 Suppl 1(Suppl 1):A2-A9. PubMed ID: 33962839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Costs of introducing and delivering HPV vaccines in low and lower middle income countries: inputs for GAVI policy on introduction grant support to countries.
    Levin A; Wang SA; Levin C; Tsu V; Hutubessy R
    PLoS One; 2014; 9(6):e101114. PubMed ID: 24968002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
    Aguilar IB; Mendoza LO; García O; Díaz I; Figueroa J; Duarte RM; Perdomo G; Garcia AG; Janusz CB
    Vaccine; 2015 May; 33 Suppl 1():A167-73. PubMed ID: 25919157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of the introduction of two-dose bi-valent (Cervarix) and quadrivalent (Gardasil) HPV vaccination for adolescent girls in Bangladesh.
    Mahumud RA; Gow J; Alam K; Keramat SA; Hossain MG; Sultana M; Sarker AR; Islam SMS
    Vaccine; 2020 Jan; 38(2):165-172. PubMed ID: 31668820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human papillomavirus (HPV) vaccine coverage achievements in low and middle-income countries 2007-2016.
    Gallagher KE; Howard N; Kabakama S; Mounier-Jack S; Burchett HED; LaMontagne DS; Watson-Jones D
    Papillomavirus Res; 2017 Dec; 4():72-78. PubMed ID: 29179873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Global impact and cost-effectiveness of one-dose versus two-dose human papillomavirus vaccination schedules: a comparative modelling analysis.
    Prem K; Choi YH; Bénard É; Burger EA; Hadley L; Laprise JF; Regan MC; Drolet M; Sy S; Abbas K; Portnoy A; Kim JJ; Brisson M; Jit M
    BMC Med; 2023 Aug; 21(1):313. PubMed ID: 37635227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Costs of the COVID-19 vaccination programme: estimates from the West Rand district of South Africa, 2021/2022.
    Edoka I; Matsela LM; Modiba K; Luther Y; Govender S; Maotoe T; Brahmbhatt H; Pisa PT; Meyer-Rath G; Miot J
    BMC Health Serv Res; 2024 Jul; 24(1):857. PubMed ID: 39075487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.